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Gene targeting: The classical approach
 
Central to an understanding of the in vivo function of genes is
their analysis by mutation, that is, inactivation or modification
of a gene by mutation and the study of the consequences of the
mutation in the mutant organism. In mammals, before gene
targeting, this approach was limited to the rare spontaneous
mutations reflected in obvious phenotypes, as in the case of in-
heritable diseases in the human. The targeted mutagenesis of
the mouse germline was thus a fundamental breakthrough in
this area of research. In its original form, gene targeting in-
volves the inactivation of a given gene in the genome of em-
bryonic stem (ES) cells by homologous recombination (1–3).
ES cells derive from an early stage of mouse development and
have retained their totipotency, thus they can participate in the
generation of cell lineages of the mouse (including germ cells)
if transferred into an early mouse embryo. Transfer of mutant
ES cells into mouse embryos thus allows the transmission of
the mutation in question into the mouse germline.
In the classical experiment of Thomas and Capecchi (3)
gene inactivation was achieved by replacing a predetermined
gene segment with a mutant version of this segment, through
homologous recombination. Since the latter is infrequent in
mammalian cells, the isolation of the mutant ES cells requires
stringent selection. This was achieved by placing a selectable
gene (in that case the neomycin resistance gene) into the tar-
geted locus in a manner that allows its expression (and hence
cellular selection) while inactivating the target gene.
 
Refining classical gene targeting by the Cre-loxP recombination 
system
 
A limitation of classical gene targeting comes from the pres-
ence of a selection marker gene in the targeted locus. Since
this gene must be active in order to allow ES cell selection, it
must always be considered that through its expression it might
affect the mutant phenotype in an unpredictable way. A par-
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Abbreviation used in this paper:
 
 ES, embryonic stem.
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ticularly serious problem arises if gene targeting is used for the
modification or elimination of regulatory DNA sequences, as
the selectable gene brings in its own promoter and enhancer.
For this reason, attempts have been made to eliminate the se-
lection marker genes from the targeted locus (4–7).
We have used the bacteriophage-derived Cre-loxP recom-
bination system (8, 9) for this purpose which had been shown
to perform well in mouse cells in vitro (10) and in vivo (11, 12)
and which appeared to offer a broad range of applications in
gene targeting. The Cre enzyme, a member of a large family of
recombinases (13), recognizes a sequence motif of 34 bp, called
loxP (9). If a DNA segment is flanked by two loxP sites in the
same orientation, Cre excises that segment from the DNA,
leaving a single loxP site behind. (A piece of DNA flanked by
loxP sites in opposite orientations will be inverted by the en-
zyme, a reaction that waits to be exploited in the gene target-
ing field [14, 15].) Considering this site as innocent, “clean” de-
letions can thus be produced. If in a gene targeting experiment
the selection marker gene on the targeting vector (subse-
quently inserted into the target locus by homologous recombi-
nation) is flanked by loxP sites, it can later be removed from
the ES cell genome via transient transfection of a Cre-expres-
sion vector into these cells. By appropriately positioning the
two loxP sites, one can use this system as a general system of
mutagenesis, producing deletions (16–18), gene replacements,
insertions (often called “knock-ins”) (19, 20), point mutations,
(21) etc. However, we shall focus here on yet another and per-
haps the most important aspect of Cre-loxP–mediated tar-
geted mutagenesis, namely conditional (rather than general)
gene targeting.
 
Conditional gene targeting
 
Why do we want to achieve conditional, i.e., cell-type–specific
and/or inducible, gene targeting beyond targeted mutagenesis
of the mouse germline? There are several reasons. First, germ-
line mutations may be lethal, in which case there is no mouse
to study gene function. Second, genes may exert their function
at several stages of ontogeny and in different cell types. In the
latter case, complex phenotypes may result, where it is difficult
to distinguish cell-autonomous from more complex lesions. In
the former case, classical gene targeting will allow one to iden-
tify the initial stage at which the target gene plays a critical
role, but not necessarily later stages. Finally, in medical re-
search, conditional gene targeting could allow one to generate
models of somatically acquired genetic diseases (such as most
forms of cancer) rather than of inherited ones.
The strategy of conditional targeting of endogenous genes
that we have developed (16) consists of flanking a target gene
or gene segment with loxP sites in ES cells by classical gene
targeting and deleting the selection marker gene by transient
transfection with a Cre-encoding plasmid. This protocol yields
ES cell mutants in which the gene segment of interest is either
flanked by loxP sites or deleted. Either mutation can be trans-
mitted into the germline. In the former case, the mutant mice
carry a functional, but loxP-flanked gene in their genome (Fig.
1 
 
A
 
). In the latter the gene is deleted in all cells of the body,
Figure 1. (A) Generation of mice with loxP-flanked target genes (flox). (1) Gene targeting vector containing three loxP sites (filled triangles), 
two of them flanking the Neomycin resistance (neo) gene. The HSV-tk gene, often used for negative selection, is not shown. (2) Target gene in 
the genome of ES cells (exons drawn as filled boxes). (3) Genomic locus modified by homologous recombination (HR) between vector and tar-
get gene. (4) Deletion of the loxP-flanked neo gene by transient Cre expression in ES cells. Two loxP sites remain in the target gene. (5) Gener-
ation of a loxP-containing mouse line from modified ES cells. (B) Utilization of Cre transgenic mice for conditional gene targeting. The mouse 
strain harboring two loxP sites in the target gene (see A) can be crossed to various strains expressing Cre recombinase. The target gene becomes 
inactivated only in cells expressing Cre but remains active in all other cells of the body. The Cre-expressing strains are described in the text.
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generating the situation of a classical knockout experiment, ex-
cept that no selection marker gene remains in the mutant locus.
Conditional targeting of loxP-flanked genes or gene seg-
ments can be achieved by crossing into the mutant animal a
Cre-transgene from which Cre recombinase is expressed in a
cell-type–specific or inducible manner (Fig. 1 
 
B
 
). The initial
experiment, done in collaboration with J. Marth’s group, es-
tablished that in principle, cell-type–specific gene targeting can
be successfully performed in this manner (lck-cre; 16). We sub-
sequently generated a Cre transgene under the control of an
interferon 
 
a
 
/
 
b
 
 (IFN
 
a
 
/
 
b
 
) inducible promoter and showed that
in this system 100% deletion of a loxP-flanked gene segment
could be achieved in the liver upon injection of IFN
 
a
 
/
 
b
 
 and up
to 98% in lymphocytes, whereas lower degrees of deletion
were seen in other tissues (MX-cre; 22). Thus, both cell-type–
specific and inducible gene targeting are feasible using the
Cre-loxP recombination system, the efficiency in the system
can reach 100% (as also recently shown by J. Marth and col-
leagues for T cell–specific gene targeting [23]) and Cre recom-
binase can do its job in resting cells such as the liver. Note also
that conditional as well as classical gene targeting can be used
not only for gene inactivation, but also, by appropriately con-
structing targeting vectors, for the introduction of subtle muta-
tions (21) and also the activation of a gene (see reference 12).
The extent to which conditional gene targeting can be ap-
plied in biological and medical research depends at this point,
at a technical level, on the availability of Cre-transgenic strains
in which Cre is expressed at sufficiently high levels, but under
strict cell-type–specific and/or inducible control. Indeed, if Cre
expression could be induced specifically in any given cell type,
that would for many purposes represent an ideal system of
conditional gene targeting. While this goal has not yet been
reached, fusion proteins in which Cre is fused to the ligand
binding domain of a steroid receptor and which can be acti-
vated inside the cell by a steroid antagonist may allow for a
successful approach to this problem (24–26). Alternatively,
one may consider using systems of inducible, cell-type–specific
transcriptional control like that developed by Bujard and col-
leagues, with tetracycline as the inducer (27, 28).
At present, a limited number of Cre transgenic animals is
available which allows gene targeting in T cells (23), B cells
(CD19-cre; 29 and R. Rickert, J. Roes, and K. Rajewsky, un-
published data), and, inducible by IFN
 
a
 
/
 
b
 
, in a variety of tis-
sues but predominantly liver and lymphocytes (22). Many
other such strains are presently being generated worldwide, so
that one can expect that a large set of Cre transgenics will soon
be at the disposition of the scientific community, making con-
ditional gene targeting a routine approach in the analysis of
mammalian gene function in vivo.
We have recently generated two Cre transgenic mouse
lines which behaved unexpectedly, but still turn out to be par-
ticularly useful in this context. The first is a strain, designated
balancer, which allows partial gene inactivation in essentially
all tissues of the body, generating a mosaic situation in which
competition between wild-type and mutant cells can be stud-
ied in situ. In a situation in which Cre-mediated deletion re-
sults in homozygous mutant cells, a simple Southern analysis
of the extent of deletion in various tissues of the mosaic mu-
tant animal allows one to pinpoint the sites at which the gene
in question plays a functionally critical role (Betz, U.A.K., C.
Voßhenrich, K. Rajewsky, and W. Müller, manuscript submit-
ted for publication). The second Cre-transgenic strain, called
deleter, mediates deletion of loxP-flanked gene segments in
essentially all cells of the body, including germ cells (30).
Crossing this strain to a strain in which a target gene is flanked
by loxP sites on one or both homologous chromosomes, one
obtains ubiquitous deletion which can also be transmitted into
the germline, producing a classical knockout, again without a
selection marker gene in the mutant locus.
Given these options of targeted mutagenesis through trans-
genes encoding Cre under various kinds of genetic control, we
now mostly perform gene targeting experiments such that only
a single mutation of the target gene is transmitted into the germ-
line, namely a loxP-flanked, functional version of the wild-type
locus. The resulting animals are healthy and indistinguishable
from the wild-type. However, by crossing them to the various
Cre-transgenics, any type of conditional mutagenesis as well as
a classical (general) knockout can be obtained. Since the pro-
duction of a strain carrying a loxP-flanked allele represents
only little more effort than that of a classical knockout, we rec-
ommend that this protocol be generally considered when gene
targeting experiments are being planned.
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